Community Trust & Investment Co. Cuts Stock Position in IQVIA Holdings Inc. $IQV

Community Trust & Investment Co. cut its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 108,911 shares of the medical research company’s stock after selling 4,528 shares during the quarter. IQVIA makes up approximately 1.1% of Community Trust & Investment Co.’s investment portfolio, making the stock its 26th largest holding. Community Trust & Investment Co. owned about 0.06% of IQVIA worth $20,687,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Asset Dedication LLC raised its stake in shares of IQVIA by 224.0% during the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after acquiring an additional 168 shares in the last quarter. Trust Co. of Toledo NA OH purchased a new stake in shares of IQVIA during the 2nd quarter valued at $39,000. J.Safra Asset Management Corp boosted its position in shares of IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares in the last quarter. Rothschild Investment LLC grew its stake in IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after buying an additional 124 shares during the last quarter. Finally, NewSquare Capital LLC increased its position in IQVIA by 185.3% during the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after buying an additional 189 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IQV has been the topic of a number of research analyst reports. Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the stock from $195.00 to $225.00 in a research note on Tuesday, September 9th. Citigroup lifted their target price on shares of IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 29th. TD Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating and upped their price target for the company from $206.00 to $215.00 in a research note on Monday, November 3rd. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Finally, Evercore ISI boosted their price objective on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $243.19.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Price Performance

Shares of IQV opened at $234.50 on Tuesday. The business’s 50-day moving average is $222.34 and its two-hundred day moving average is $198.36. The company has a market capitalization of $39.93 billion, a P/E ratio of 32.17, a P/E/G ratio of 2.29 and a beta of 1.36. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $234.95. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.